Keen Vision Acquisition Corporation

What they do

Keen Vision Acquisition Corp. is a BVI-incorporated special purpose acquisition company (SPAC) that raised $149.5 million in an IPO in July 2023 to effect a merger or acquisition. It has not yet selected a business combination target, though it signed a non-binding letter of intent in March 2024 with a clinical-stage biopharmaceutical company in Boston focused on stem cell bioengineering and cell/gene therapies. The company's operations consist solely of identifying and completing a business combination.

Revenue drivers

• No operating revenue — As a blank check company, Keen Vision has no product or service revenue; income is derived from interest earned on trust account proceeds.
• IPO proceeds and private placement — Gross proceeds of $149.5 million from IPO units and $6.79 million from private placement units fund the trust and operations.
• Business combination target — The company intends to generate shareholder value by completing a merger with a target; the only disclosed candidate is a Boston biopharmaceutical firm.

Recent performance

For the year ended 2025, the company reported net income of $1.9 million, down from $7.4 million in 2024. Operating cash flow was negative $784,137 in 2025, following negative $1.1 million in 2024. As of March 31, 2026, total assets were $13.3 million, total liabilities were $7.5 million, and shareholders' equity was negative $7.4 million. Cash and equivalents were only $9,098 at that date, indicating that the company has largely depleted its operating cash.

Strategy

Management is focused on completing an initial business combination within the allowed timeframe, and the company has not limited its search to a particular industry or geography. It is evaluating a potential merger with the Boston biopharmaceutical target described in the LOI, though no definitive agreement has been executed. The company may engage its sponsor, KVC Sponsor LLC, as a financial advisor, and may seek additional financing to close a transaction. It also has the option of an automatic six-month extension after signing the LOI to complete the deal.

Risks

• No deal completed — The company has not consummated a business combination and may fail to do so within the required timeframe, leading to liquidation.
• Deficient equity — Shareholders' equity is negative $7.4 million as of March 31, 2026, which may raise going-concern doubts.
• Dependence on non-binding LOI — The only disclosed target negotiation is a non-binding letter of intent, which can be terminated or fail to lead to a definitive agreement.
• Nasdaq delisting risk — The company received a delisting notice in July 2026, indicating potential listing failure that could impair its ability to raise capital or complete a deal.

Outlook

Management has not provided revenue or operational guidance. The company plans to pursue its initial business combination, and the LOI may lead to definitive agreements with the Boston biopharmaceutical target. The company has limited cash on hand and may need additional funding to support operations and transaction costs. Given the recent delisting notice, there is material uncertainty about the company's ability to continue as a going concern.